• Earlier this month, Exact Sciences introduced Cancerguard™, a multi-cancer early detection blood test, entering direct competition with NeoGenomics in the oncology diagnostics market.
• This development follows NeoGenomics' recent legal win enabling broader commercialization of its RaDaR® ST assay, highlighting the rapidly intensifying competition in the multi-cancer testing segment.
• We'll explore how the emergence of a major new competitor in early cancer detection may impact NeoGenomics' industry positioning and outlook.

We've found 18 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

NeoGenomics Investment Narrative Recap

To be interested in NeoGenomics as a shareholder, you likely need to believe that expansion in precision oncology and continued innovation in multi-cancer liquid biopsy testing can drive both clinical volume growth and improved financial results. However, Exact Sciences' recent entry into early cancer detection intensifies competition precisely as the ramp-up of RaDaR® ST is viewed as the key short-term catalyst. The impact is material, underscoring one of the company’s top risks: increased pressure on market share and margins from better-capitalized rivals.

Among NeoGenomics’ latest product announcements, the July 2025 launch of NEO PanTracer™ LBx stands out. This liquid biopsy panel targets therapy selection and disease monitoring using genomic profiling across more than 500 genes, positioning the company to capitalize on the rising need for advanced cancer diagnostics, yet also placing its results and market adoption under close scrutiny in the face of new competition.

By contrast, investors should be aware that intensified rivalry in oncology diagnostics could affect not just sales growth, but also...

NeoGenomics' narrative projects $893.1 million revenue and $48.1 million earnings by 2028. This requires 9.0% yearly revenue growth and a $152.1 million earnings increase from -$104.0 million currently.

Uncover how NeoGenomics' forecasts yield a $9.78 fair value, a 23% upside to its current price.

Exploring Other Perspectives

Four individual fair value estimates from the Simply Wall St Community span from US$9.78 to US$74.69 per share. This diversity reflects how investor views can vary dramatically, especially given current concerns over growing competitive threats and the outlook for future revenue growth.

Explore 4 other fair value estimates on NeoGenomics - why the stock might be worth just $9.78!

Build Your Own NeoGenomics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your NeoGenomics research is our analysis highlighting 2 important warning signs that could impact your investment decision.
• Our free NeoGenomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate NeoGenomics' overall financial health at a glance.

Looking For Alternative Opportunities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.